Related Experiment Videos
2-Chlorodeoxyadenosine therapy in Waldenstrom's macroglobulinaemia
A Delannoy1, A Ferrant, P Martiat
1Groupe d'Hématologie de l'Université Catholique de Louvain, Cliniques Universitaires St. Luc, Brussels, Belgium.
Nouvelle Revue Francaise D'Hematologie
|August 1, 1994
Summary
2-chlorodeoxyadenosine (CdA) showed limited efficacy and severe hematological toxicity in Waldenström's macroglobulinaemia (WM) patients. This clinical trial found a lower response rate and more severe side effects than previously reported.
Area of Science:
- Hematology
- Oncology
- Clinical Trials
Background:
- Waldenström's macroglobulinaemia (WM) is a rare lymphoproliferative disorder.
- Experience with 2-chlorodeoxyadenosine (CdA) in WM treatment is limited.
- Previous studies suggested encouraging results for CdA in WM.
Purpose of the Study:
- To evaluate the efficacy and safety of 2-chlorodeoxyadenosine (CdA) in Waldenström's macroglobulinaemia (WM).
- To assess response rates and hematological toxicity in a cohort of WM patients treated with CdA.
Main Methods:
- A clinical trial involving 18 WM patients (13 previously treated, 5 untreated).
- CdA administered via continuous intravenous infusion (4 mg/m2/day for 7 days) or 2-h intravenous infusions (5.6 mg/m2/day for 5 days).
- Patient characteristics, response, and toxicity were monitored.
Main Results:
- Partial response observed in 7 out of 18 patients.
- No correlation found between response and patient characteristics.
- Significant hematological toxicity: grade 4 neutropenia in 4 patients and thrombocytopenia in 6 patients during the first course.
Conclusions:
- CdA demonstrated a lower overall response rate in this series compared to previous reports.
- Hematological toxicity was more severe than anticipated.
- Further investigation into CdA's role in WM treatment is warranted, considering its toxicity profile.